Which patients with hepatitis B (HBV) (Hep B) have a better response to pegylated IFN-a 2a (PEG-IFN-a 2a)?

Updated: Jun 08, 2021
  • Author: Nikolaos T Pyrsopoulos, MD, PhD, MBA, FACP, AGAF; Chief Editor: BS Anand, MD  more...
  • Print

It appears that patients infected with HBV genotype A or B have a better response to IFN treatment than do patients infected with genotype C or D. This therapy also appears to be more appealing, especially for patients with increased ALT levels.

PEG-IFN-a 2a is also indicated for treatment of chronic hepatitis C, alone or in combination with ribavirin, in patients not previously treated with IFN-a, with compensated liver disease, or with HDV infection. At most, 17% of patients have durable suppression of the virus as defined by undetectable HBV DNA at 5 years posttreatment. [71, 72]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!